Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients
Author:
Funder
Health Commission of Heilongjiang Province
Publisher
Elsevier BV
Subject
Gastroenterology,Hepatology
Reference24 articles.
1. Gastric cancer;Smyth;Lancet,2020
2. Gastrointestinal stromal tumours;Blay;Nat Rev Dis Primers,2021
3. Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions;Murphy;Nat Rev Gastroenterol Hepatol,2018
4. Locoregional gastric cancer: a narrative review of multidisciplinary management;Pelcovits;Ann Transl Med,2020
5. Gastric cancer etiology and management in Asia and the West;Russo;Annu Rev Med,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. C-reactive protein flare-response predicts the efficacy of PD-1/PD-L1 monoclonal antibodies in metastatic gastric cancer;2024-07-16
2. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis;BMC Cancer;2024-05-17
3. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab;Frontiers in Immunology;2024-04-05
4. Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer;Anti-Cancer Drugs;2023-11-13
5. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third‐line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study;Journal of Clinical Pharmacy and Therapeutics;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3